Aimovig (Erenumab-aooe) - Subcutaneous

What Is Aimovig?

Aimovig (erenumab-aooe) is a U.S. Food and Drug Administration (FDA)-approved medication to prevent migraine headaches. It is injected under the skin (subcutaneously) once a month.

Aimovig is a biologic medication that can affect cells at the molecular level. It is more specifically referred to as a monoclonal antibody that targets a specific protein in the brain called calcitonin gene-related peptide (CGRP). CGRP is directly related to causing a migraine attack. Aimovig is an agent that blocks the receptor where this protein binds, preventing migraines.

Drug Facts

Generic Name: Erenumab-aooe

Brand Name(s): Aimovig

Drug Availability: Prescription

Therapeutic Classification: Calcitonin gene-related peptide receptor antagonist

Available Generically: No

Controlled Substance: N/A

Administration Route: Subcutaneous

Active Ingredient: Erenumab-aooe

Dosage Form(s): Autoinjector

What Is Aimovig Used For?

Aimovig prevents migraine headaches with a once-monthly injection. It is currently only used for adults dealing with occasional (episodic) or chronic migraines.

How to Take Aimovig

Take Aimovig as an injection under the skin of a fatty area, such as your stomach, upper back of the arms, or the thigh area. Follow these instructions when using the medication:

  • If you store this medication in the refrigerator, take it out and leave it at room temperature for at least 30 minutes before injecting it to minimize pain.
  • Inspect the medication for any color changes or particles before injecting.
  • Do not inject it within two inches of the belly button.
  • Throw away used needles in a needle/sharp disposal box or similar containers, like a milk jug.
  • Do not use the device more than once, as each injection is meant for one-time use only.

It is best to speak with your healthcare provider before using this medication. They can provide detailed guidance on how to administer it before initial use.


Before its first use, store Aimovig in the refrigerator between 36 F and 46 F in its original packaging to protect it from the light. Once you remove it from the refrigerator, keep it at room temperature (between 68 F and 77 F) in its original packaging. You must use it within seven days if leaving it at room temperature. After seven days, discard the medication.

Do not store Aimovig in the freezer or the car if temperatures are not within the recommended refrigeration temperature.

Off-Label Uses

Aimovig is not FDA-approved to treat or prevent cluster headaches or other forms of migraines, such as vestibular migraines. However, if other medications fail, healthcare providers may prescribe Aimovig for these purposes. This is known as off-label use.

Aimovig and CGRP blockers are approved to prevent migraines. However, they may also help prevent cluster headaches.

Newer treatments like CGRP blockers for migraine headaches are currently being reviewed for treating vestibular migraines, which are associated with headaches that involve vertigo, dizziness, and balance disturbances. Further studies are needed, but these anti-CGRP medications have shown promise in treating multiple forms of migraine headaches.

How Long Does Aimovig Take to Work?

Aimovig may take effect within the first month of use. However, it can take two to three months of treatment to feel significant improvements. If you do not experience a difference in the number of migraines after three months, talk to your healthcare provider, as this medication may not be best for you.

What Are the Side Effects of Aimovig?

This is not a complete list of side effects, and others may occur. A healthcare provider can advise you on side effects. If you experience other effects, contact your pharmacist or a healthcare provider. You may report side effects to the FDA at or 800-FDA-1088.

Common Side Effects

Common side effects of Aimovig include:

  • Injection site reactions (e.g., redness, swelling, or itchiness)
  • Constipation
  • Cramps or muscle spasms

Severe Side Effects

Call your healthcare provider immediately if you have serious side effects. Call 911 if your symptoms feel life-threatening or if you think you’re having a medical emergency. Serious side effects can include the following:

  • Hypersensitivity reactions (e.g., rash, swelling of the face, and anaphylaxis)
  • Constipation with severe complications, such as hospitalization
  • High blood pressure, which can cause symptoms such as a bad headache, vision changes, or passing out

Long-Term Side Effects

Immunogenicity is a rare but serious side effect that can occur while taking monoclonal antibodies. Immunogenicity is the ability of a foreign substance, such as Aimovig, to provoke an immune response. This could render your medication ineffective or even cause more harm than good.

Report Side Effects

Aimovig may cause other side effects. Call your healthcare provider if you have any unusual problems while taking this medication.

If you experience a serious side effect, you or your healthcare provider may send a report to the FDA's MedWatch Adverse Event Reporting Program or by phone (800-332-1088).

Dosage: How Much Amovig Should I Take?

Drug Content Provided by IBM Micromedex®

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

  • For injection dosage form (solution):
    • For migraine headaches:
      • Adults—70 milligrams (mg) injected under the skin once a month. Some patients may be given 140 mg injected under the skin once a month.
      • Children—Use and dose must be determined by your doctor.


Certain factors may influence how your healthcare provider prescribes or doses your medication. The following are considerations for dosing adjustments as applied to Aimovig.


The safety and efficacy of Aimovig in this population have not yet been fully established. Different treatments may need to be considered if your child is dealing with migraines.

People 65 Years and Older

Data on the use of Aimovig in older adults (65 and above) is limited. The general recommendation is to start at a lower dose. A healthcare provider may need to monitor liver, kidney, and heart function.

Missed Dose

If you miss your usual dose of monthly Aimovig, take it as soon as you remember to. After that, you may take your Aimovig once each month from the date of your most recent dose.

Overdose: What Happens If I Take Too Much Aimovig?

Aimovig should not be taken beyond what was prescribed by your healthcare provider. Since this medication is only given once a month, it is rare to overdose on it.

However, if you accidentally take more than prescribed, contact a healthcare provider immediately or dial 911 if you experience severe symptoms.

What Happens If I Overdose on Aimovig?

If you think you or someone else may have overdosed on Aimovig, call a healthcare provider or the Poison Control Center (800-222-1222).

If someone collapses or isn't breathing after taking Aimovig, call 911 immediately.


Drug Content Provided by IBM Micromedex®

It is very important that your doctor check your progress at regular visits to make sure that this medicine is working properly and to check for unwanted effects.

The needle shield within the white or orange cap of the autoinjector and gray needle cap of the prefilled syringe contains dry natural rubber (a derivative of latex), which may cause allergic reactions in people who are sensitive to latex. Tell your doctor if you have a latex allergy before using this medicine.

This medicine may cause serious allergic reactions, including anaphylaxis and angioedema, which can be life-threatening and require immediate medical attention. Tell your doctor right away if you have a rash, itching, hoarseness, trouble breathing, trouble swallowing, or any swelling of your hands, face, or mouth after using this medicine.

Erenumab-aooe may increase your risk of having severe constipation, especially when given with medicines that decrease bowel movement. Talk with your doctor if this is a concern for you.

Check with your doctor right away if you have blurred vision, dizziness, nervousness, headache, pounding in the ears, or slow or fast heartbeat. These could be symptoms of high blood pressure.

What Are Reasons I Shouldn’t Take Aimovig?

Do not take Aimovig if you are allergic to its main ingredient, erenumab aooe. If you develop an allergic reaction while taking it, stop your medication as soon as possible.

What Other Medications Interact With Aimovig?

Aimovig is a relatively safe medication. It does not interact with many medications or common metabolites of the body, referred to as cytochrome P450 enzymes. These enzymes help break down drugs, toxins, and various chemical compounds.

There are currently no documented drug interactions with Aimovig. However, drugs associated with the same class or that have properties similar to the effect of a CGRP blocker should generally not be taken with Aimovig.

What Medications Are Similar?

Aimovig is a monoclonal antibody and CGRP blocker. Other medications that have effects similar to Aimovig include:

Frequently Asked Questions

  • What is Aimovig used for?

    Aimovig is used to prevent acute or chronic migraine headaches in adults.

  • How does Aimovig work?

    Aimovig works by blocking the receptor responsible for the inflammation process. This prevents the start of a migraine attack in the brain.

  • What drugs should not be taken with Aimovig?

    Drugs associated with the same class or that have properties similar to the effect of a CGRP blocker should not be taken with Aimovig. If you are unsure about taking this medication, speak with your pharmacist or healthcare provider before starting this medication.

  • How long does it take for Aimovig to work?

    This medication may work within the first month but more noticeably takes effect after the second and third doses (two to three months).

  • How to stop taking Aimovig?

    Do not stop taking Aimovig unless directed by your healthcare provider or if you experience severe side effects, such as swelling, trouble breathing, or severe constipation.

  • Should I stop my other medications while taking Aimovig?

    Do not stop taking your other medications unless directed by your healthcare provider first. This medication is relatively safe to take with others, but it is always best to consult your healthcare provider before discontinuing any other medical treatments.

How Can I Stay Healthy While Taking Aimovig?

Migraines can be an uncomfortable and debilitating condition. Getting ahead of your migraine attacks can help improve your quality of life. This can involve a combination of prescription medications, lifestyle changes, and other alternative medicine approaches.

Try to avoid migraine triggers. Migraine triggers can include:

  • Bright lights
  • Spending long amounts of time in front of a screen
  • Stress and anxiety
  • Irregular sleep
  • Skipping meals
  • Increased caffeine intake

Additionally, some people use complementary strategies, such as acupuncture or biofeedback training, and practices, such as yoga or meditation.

Talk to your healthcare team about other ways to prevent or manage migraine attacks.

Medical Disclaimer

Verywell Health's drug information is meant for educational purposes only and is not intended to replace medical advice, diagnosis, or treatment from a healthcare provider. Consult your healthcare provider before taking any new medication(s). IBM Watson Micromedex provides some of the drug content, as indicated on the page.

The author would like to recognize and thank Jaycob Pena for contributing to this article.

4 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. U.S. Food and Drug Administration. Aimovig label.

  2. Yuan H, Spare NM, Silberstein SD. Targeting CGRP for the prevention of migraine and cluster headache: a narrative review. Headache. 2019;59 Suppl 2:20-32. doi:10.1111/head.13583

  3.  Hoskin JL, Fife TD. New anti-CGRP medications in the treatment of vestibular migraine. Front Neurol. 2022; 12:799002. doi:10.3389/fneur.2021.799002

  4. Cohen JM, Ning X, Kessler Y, et al. Immunogenicity of biologic therapies for migraine: a review of current evidence. J Headache Pain 22, 3 (2021). doi:10.1186/s10194-020-01211-5